Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology

  • Authors:
    • Debo Chen
    • Fenglin Chen
    • Xingrong Lu
    • Xiaosong Yang
    • Zhongbin Xu
    • Jie Pan
    • Ying Huang
    • Huiming Lin
    • Pan Chi
  • View Affiliations

  • Published online on: August 1, 2010     https://doi.org/10.3892/ijo_00000684
  • Pages: 355-365
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Differential protein expression was analyzed in carcinoma tissue to determine the correlation between protein levels and the clinical and pathological parameters of patients with colorectal carcinomas (CRC). Two-dimensional electrophoresis (2-DE) revealed 40 protein spots that were differentially expressed at two or greater fold difference in CRC that were identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/TOF MS). Among these proteins, prohibitin (PHB) was found to be overexpressed in CRC. It was selected for Western blot and immunohistochemistry assay in subsequent tissue microassays (TMA). Thirty-five distinct proteins were differentially expressed at least 2-fold among normal and CRC tissues. The expression of 17 proteins, including PHB, was increased by >2-fold in CRC tissues (p<0.01). Immunohistochemistry and Western blot assays found that PHB was overexpressed in CRC cases, and the expression was higher than adenoma and normal tissues (p<0.01), whereas there was no significant difference in expression of PHB between adenoma and normal tissues. Immunohistochemistry also suggested a link between PHB expression and poor differentiation (p<0.01). However, there was no difference in UICC stage, or location of CRC. Survival analysis suggested no significant correlation between PHB expression and poor prognosis. In summary, the overexpression of PHB might be associated with the transformation process from adenoma to CRC. Further, it is a potential diagnostic and differentiation biomarker of CRC in the clinic.

Related Articles

Journal Cover

August 2010
Volume 37 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen D, Chen F, Lu X, Yang X, Xu Z, Pan J, Huang Y, Lin H and Chi P: Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology. Int J Oncol 37: 355-365, 2010.
APA
Chen, D., Chen, F., Lu, X., Yang, X., Xu, Z., Pan, J. ... Chi, P. (2010). Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology. International Journal of Oncology, 37, 355-365. https://doi.org/10.3892/ijo_00000684
MLA
Chen, D., Chen, F., Lu, X., Yang, X., Xu, Z., Pan, J., Huang, Y., Lin, H., Chi, P."Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology". International Journal of Oncology 37.2 (2010): 355-365.
Chicago
Chen, D., Chen, F., Lu, X., Yang, X., Xu, Z., Pan, J., Huang, Y., Lin, H., Chi, P."Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology". International Journal of Oncology 37, no. 2 (2010): 355-365. https://doi.org/10.3892/ijo_00000684